Kazia Therapeutics Limited (KZIA): Price and Financial Metrics


Kazia Therapeutics Limited (KZIA): $6.08

0.24 (+4.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KZIA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KZIA Stock Summary

  • Of note is the ratio of Kazia Therapeutics Ltd's sales and general administrative expense to its total operating expenses; merely 7.75% of US stocks have a lower such ratio.
  • For KZIA, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • Revenue growth over the past 12 months for Kazia Therapeutics Ltd comes in at 1,551.25%, a number that bests 99.29% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to KZIA, based on their financial statements, market capitalization, and price volatility, are CDTX, ORGS, IVA, GOVX, and ERYP.
  • KZIA's SEC filings can be seen here. And to visit Kazia Therapeutics Ltd's official web site, go to www.kaziatherapeutics.com.

KZIA Stock Price Chart Interactive Chart >

Price chart for KZIA

KZIA Price/Volume Stats

Current price $6.08 52-week high $12.28
Prev. close $5.84 52-week low $5.01
Day low $5.89 Volume 25,766
Day high $6.20 Avg. volume 17,937
50-day MA $6.80 Dividend yield N/A
200-day MA $8.50 Market Cap 80.26M

Kazia Therapeutics Limited (KZIA) Company Bio


Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.


KZIA Latest News Stream


Event/Time News Detail
Loading, please wait...

KZIA Latest Social Stream


Loading social stream, please wait...

View Full KZIA Social Stream

Latest KZIA News From Around the Web

Below are the latest news stories about Kazia Therapeutics Ltd that investors may wish to consider to help them evaluate KZIA as an investment opportunity.

Kazia Therapeutics to be ‘transformed’ by pipeline progress

Kazia Therapeutics says it had $15.2 million in cash at the end of December 2021 having committed $11.4 million during the period to progress its

Mirage News | February 24, 2022

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 7, 2022

KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022.

Yahoo | February 7, 2022

KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the Edison Group 'Open House' Event, to be held virtually from 25-27 January 2022.

Yahoo | January 25, 2022

KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 January 2022. The company has been invited to participate via a 'fireside chat' with a senior equity research analyst at the bank.

Yahoo | January 7, 2022

Read More 'KZIA' Stories Here

KZIA Price Returns

1-mo -10.72%
3-mo -9.93%
6-mo -38.59%
1-year -35.46%
3-year 87.92%
5-year 72.73%
YTD -27.79%
2021 -2.55%
2020 99.08%
2019 78.60%
2018 -23.58%
2017 -45.92%

Continue Researching KZIA

Want to see what other sources are saying about Kazia Therapeutics Ltd's financials and stock price? Try the links below:

Kazia Therapeutics Ltd (KZIA) Stock Price | Nasdaq
Kazia Therapeutics Ltd (KZIA) Stock Quote, History and News - Yahoo Finance
Kazia Therapeutics Ltd (KZIA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6136 seconds.